Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long term stocks. Dividend-paying stocks have traditionally been seen as a solid ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Eli Lilly is trying to avoid that problem this time around with orforglipron. The company has been building up a stockpile of the pills. It recently disclosed inventory, valued at nearly $550 ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

The company expects those regulatory filings to come by the end of the year for obesity and in 2026 for diabetes. What it means: Current GLP-1 drugs used for weight loss, including Eli Lilly's ...